Fusion Antibodies Limited

Hoffmann-la Roche Inc.

Purdue Pharma L.p.

Richard John Buick

Michael Schraeml

Birgit Bossenmaier

Michael Gerg

Christopher Scott

Shane Olwill

James Johnston

Carmen Peess

Wolfgang Schaefer

Stefan Dengl

Thomas Jorg Mehrling

Gerhard Niederfellner

Claudio Sustmann

Daniel A Soltis

Frank Kroner

Thomas Jaquin

Declan Doherty

Hangfai Kwok

Darragh MacCann

Leona McGirr

Hugh Morgan

James McClory

Natasha Campbell

Anthony O'Kane

Jill Caswell

This disclosure relates to methods of generating antibody libraries, antibody libraries produced using such methods, and variant antibodies. Presently, methods of improving antibody binding (affinity maturation assays) require the screening of vast libraries of antibody variants (often >10) to identify a small fraction of variants with improved characteristics. The present invention involves taking the nucleotide sequence of the framework and complementarity determining region of a target antibody and identifying motifs which would be recognised by deamination somatic hypermutation enzymes. A small library of variants is then created which incorporate one or more of these mutations. It was found that a relatively high proportion of the variants have an increased affinity. The technique of the present invention was demonstrated on the trastuzumab and Cathepsin S antibodies, and the variants produced are also claimed.

Antibody library and method

The present disclosure provides humanized antibodies and antibody-drug conjugates that specifically bind to human tissue factor, and which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the disclosed humanized antibodies and antibody-drug conjugates in the treatment of cancer.

Humanized antibodies targeting human tissue factor

The invention relates to HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2, their preparation and use as medicament.

HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2

The invention relates to specific anti-HER3 antibodies, that bind to the beta-hairpin of HER3, their preparation and use as medicament.

Anti-HER3 antibodies binding to the beta-hairpin of HER3

Described are cross-specific antibody molecules with binding specificity for both AREG and HBEGF. The antibody molecules may be used in methods of treatment of cancer and diseases associated with angiogenesis.

Anti-AREG/HB-EGF antibodies and treatment

The invention relates to the identification of mycobacterial antigens which are highly immunogenic and which may be used in assays and methods for the diagnosis of tuberculosis and the discrimination between infected animals and animals previously exposed to vaccines.

Assays for diagnosis of tuberculosis and uses thereof

Growing community of inventors

Belfast, United Kingdom

Richard John Buick